Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
- 1 April 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 82 (4) , 361-369
- https://doi.org/10.1016/s1081-1206(10)63285-1
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- An evaluation of zafirlukast in the treatment of asthma with exploratory subset analysesPublished by Elsevier ,1999
- Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstructionJournal of Allergy and Clinical Immunology, 1998
- Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind TrialArchives of internal medicine (1960), 1998
- Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1997
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate AsthmaAnnals of Internal Medicine, 1997
- Worldwide Clinical Experience With the First Marketed Leukotriene Receptor AntagonistChest, 1997
- Leukotrienes in asthma. The potential therapeutic role of antileukotriene agentsArchives of internal medicine (1960), 1996
- Standardization of Spirometry, 1994 Update. American Thoracic Society.American Journal of Respiratory and Critical Care Medicine, 1995
- Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.American Journal of Respiratory and Critical Care Medicine, 1994